Ibrahim Ahmad, Noun Peter, Khalil Charbel, Taher Ali
Division of Hematology-Oncology, Department of Medicine, Lebanese and Arab Universities, Beirut, Lebanon.
Cancer Center and Bone Marrow Transplantation (BMT) Program at Middle East Institute of Health, Bsalim, Lebanon.
Front Oncol. 2021 Mar 15;11:564383. doi: 10.3389/fonc.2021.564383. eCollection 2021.
COVID-19 caused by SARS-Cov-2 is a devastating infection in patients with hematological malignancies. In 2018, the Lebanese Society of Hematology and Blood Transfusion (LSHBT) updated the guidelines for the management of hematological malignancies in Lebanon. In 2019, it was followed by a second update. Given the rapidly changing evidence and general situation for COVID-19, the LSHBT established some recommendations and suggestions for the management of the patients with hematological malignancies taking into account the Lebanese condition, economic situation, and the facts that SARS-Cov-2 infection has apparently been devastating. In this article we present recommendations and proposals to reduce or to manage SARS-Cov-2 infection in the patients with myeloid and lymphoid hematological malignancies.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）对血液系统恶性肿瘤患者来说是一种极具破坏性的感染。2018年，黎巴嫩血液学和输血学会（LSHBT）更新了黎巴嫩血液系统恶性肿瘤管理指南。2019年，又进行了第二次更新。鉴于COVID-19的证据和总体情况迅速变化，LSHBT考虑到黎巴嫩的国情、经济状况以及SARS-CoV-2感染显然具有毁灭性这一事实，为血液系统恶性肿瘤患者的管理制定了一些建议。在本文中，我们提出减少或管理髓系和淋巴系血液系统恶性肿瘤患者SARS-CoV-2感染的建议和提议。
